PYC THERAPEUTICS LIMITED — Capital/Financing Update 2023

Mar 6, 2023

==> picture [595 x 180] intentionally omitted <==

----- Start of picture text ----- 31 October 7 March 202 2 3----- End of picture text -----

ASX Announcement The Manager Company Announcements Office Australian Securities Exchange 20 Bridge Street SYDNEY NSW 2000

Dear Sir or Madam

NOTIFICATION UNDER TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001

This notice is given by PYC Therapeutics Limited (ACN 098 391 961), ( ASX:PYC ) ( ‘PYC’ or ‘the Company ’) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (‘ the Act ”).

PYC today released an Appendix 2A for the issue of 6,486,487 shares relating to the conversion of unquoted options. The options were convertible at an exercise price of $0.06 and $0.063 each with an expiry date of 28 February 2023. These securities above were issued without disclosure under Part 6D.2 of the Corporation Act.

PYC gives notice under section 708A(5)(e) of the Act that:

• (a) The shares were issued without disclosure to investors under Part 6D.2 of the Act;

• (b) As a disclosing entity, PYC is subject to regular reporting and disclosure obligations;

• (c) As at the date of this notice, PYC has complied with the provisions of Chapter 2M as they apply to PYC and section 674 of the Act; and

• (d) As at the date of his notice, there is no information that is ‘excluded information’ within the meaning of section 708A(7) and 708A(8) of the Act which is required to be disclosed by Po Valley under section 708A(6)(e) of the Act.

Approved and authorised for release by the Board of Directors of PYC Therapeutics Limited

Kevin Hart Company Secretary

1

+61 8 6151 0994 | pyctx.com | ACN 098 391 961

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating precision medicines for patients with major unmet needs in genetic disease. The Company’s platform combines a novel drug delivery technology with the rapidly growing RNA therapeutic class to create a pipeline of first-in-class drugs that address the root cause of the targeted disease.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials and is now progressing multiple ‘fast-follower’ programs into the clinic. For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

CONTACTS:

INVESTORS and MEDIA info@pyctx.com

2

+61 8 6151 0992 | pyctx.com | ACN 098 391 961